United Therapeutics - UTHR Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $294.67
Forecasted Upside: 37.45%
Number of Analysts: 9
Breakdown:
2 Sell Ratings
0 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$214.38 As of 06/2/2023 11:45 AM ET

▲ +0.9 (0.42%)

1 month | 3 months | 12 months

Get New United Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for UTHR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UTHR

^$294.67

▲ +37.45% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is $294.67, with a high forecast of $375.00 and a low forecast of $230.00. The average price target represents a 37.45% upside from the last price of $214.38.

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in United Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/8/2021

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/8/2022

0 strong buy ratings
6 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/6/2022

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/4/2022

0 strong buy ratings
7 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

12/3/2022

0 strong buy ratings
8 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

3/3/2023

0 strong buy ratings
8 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

5/2/2023

0 strong buy ratings
7 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

6/1/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/4/2023	LADENBURG THALM/SH SH	Lower Target		$285.00 ➝ $256.00	Low
4/21/2023	Argus	Lower Target	Buy	$300.00 ➝ $280.00	Low
4/10/2023	UBS Group	Lower Target	Buy	$330.00 ➝ $310.00	Low
4/10/2023	Morgan Stanley	Lower Target	Overweight	$320.00 ➝ $316.00	Low
2/23/2023	JPMorgan Chase & Co.	Boost Target	Overweight	$265.00 ➝ $280.00	Low
2/23/2023	Morgan Stanley	Lower Target	Overweight	$330.00 ➝ $320.00	Low
2/23/2023	HC Wainwright	Reiterated Rating	Buy	$300.00	Low
2/23/2023	LADENBURG THALM/SH SH	Lower Target		$295.00 ➝ $285.00	Low
1/11/2023	Argus	Boost Target	Buy	$250.00 ➝ $300.00	Low
12/6/2022	Morgan Stanley	Boost Target	Overweight	$322.00 ➝ $330.00	Low
12/6/2022	UBS Group	Initiated Coverage	Buy	$320.00	Low
12/5/2022	The Goldman Sachs Group	Initiated Coverage	Sell	$230.00	Low
11/3/2022	JPMorgan Chase & Co.	Boost Target	Overweight	$240.00 ➝ $265.00	Low
11/3/2022	Morgan Stanley	Boost Target	Overweight	$288.00 ➝ $322.00	Low
11/3/2022	Wedbush	Boost Target		$250.00 ➝ $305.00	Low
11/3/2022	Oppenheimer	Boost Target	Outperform	$325.00 ➝ $375.00	Low
11/3/2022	HC Wainwright	Boost Target	Buy	$255.00 ➝ $300.00	Low
10/11/2022	Morgan Stanley	Initiated Coverage	Overweight	$288.00	Low
9/20/2022	Bank of America	Reiterated Rating	Underperform		Low
9/19/2022	Wedbush	Reiterated Rating	Outperform	$263.00	Low
5/24/2022	Jefferies Financial Group	Boost Target		$223.00 ➝ $245.00	High
5/24/2022	JPMorgan Chase & Co.	Boost Target		$225.00 ➝ $238.00	High
5/24/2022	Wedbush	Boost Target	Outperform	$236.00 ➝ $263.00	High
5/24/2022	Credit Suisse Group	Boost Target	Outperform	$219.00 ➝ $247.00	High
5/24/2022	HC Wainwright	Boost Target	Buy	$248.00 ➝ $255.00	High
5/5/2022	Oppenheimer	Boost Target		$275.00 ➝ $300.00	Low
4/19/2022	JPMorgan Chase & Co.	Lower Target	Overweight	$230.00 ➝ $223.00	High
2/27/2022	Wedbush	Reiterated Rating	Buy	$276.00 ➝ $236.00	Medium
2/25/2022	HC Wainwright	Reiterated Rating	Buy		Medium
2/25/2022	LADENBURG THALM/SH SH	Lower Target	Buy	$231.00 ➝ $203.00	Low
2/11/2022	BTIG Research	Initiated Coverage	Neutral		Low
7/14/2021	Argus	Upgrade	Hold ➝ Buy	$205.00	Low
5/6/2021	HC Wainwright	Boost Target	Buy	$195.00 ➝ $248.00	High
4/8/2021	JPMorgan Chase & Co.	Boost Target	Positive ➝ Overweight	$185.00 ➝ $212.00	High
2/25/2021	Wedbush	Boost Target	Outperform	$255.00 ➝ $260.00	Low
2/22/2021	Credit Suisse Group	Boost Target	Outperform	$169.00 ➝ $196.00	Low
2/16/2021	Oppenheimer	Boost Target	Outperform	$200.00 ➝ $275.00	Low
2/1/2021	HC Wainwright	Upgrade	Neutral ➝ Buy	$125.00 ➝ $195.00	Low
1/20/2021	Oppenheimer	Boost Target	Outperform	$175.00 ➝ $200.00	Low
1/20/2021	Cowen	Boost Target	Outperform	$160.00 ➝ $200.00	Low
1/20/2021	LADENBURG THALM/SH SH	Boost Target	Positive ➝ Buy	$151.00 ➝ $199.00	Low
10/29/2020	Wedbush	Boost Target	Outperform	$247.00 ➝ $255.00	Low
10/29/2020	Oppenheimer	Boost Target	Outperform	$165.00 ➝ $175.00	Medium
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight		High
7/30/2020	Oppenheimer	Boost Target	Outperform	$155.00 ➝ $165.00	Low
7/29/2020	Wedbush	Reiterated Rating	Buy	$243.00 ➝ $244.00	Low
6/25/2020	Wedbush	Reiterated Rating	Buy	$243.00	High
6/25/2020	Credit Suisse Group	Boost Target	Outperform	$129.00 ➝ $145.00	Medium
6/25/2020	HC Wainwright	Boost Target	Neutral	$85.00 ➝ $125.00	Medium
6/24/2020	Oppenheimer	Initiated Coverage	Buy	$155.00	Medium
6/17/2020	Wedbush	Reiterated Rating	Buy	$243.00	High
6/12/2020	Cowen	Reiterated Rating	Buy	$145.00	Medium
4/30/2020	Wedbush	Reiterated Rating	Buy	$243.00	Low
4/30/2020	Credit Suisse Group	Reiterated Rating	Buy		Low
3/10/2020	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$115.00 ➝ $123.00	High
3/4/2020	Wedbush	Reiterated Rating	Buy	$243.00	Low
2/27/2020	Cowen	Upgrade	Market Perform ➝ Outperform	$119.00 ➝ $145.00	High
2/24/2020	Wedbush	Reiterated Rating	Outperform ➝ Buy	$237.00 ➝ $243.00	High
2/13/2020	Credit Suisse Group	Boost Target	Outperform	$113.00 ➝ $121.00	Low
2/3/2020	Wedbush	Reiterated Rating	Buy	$237.00	Low
1/31/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$116.00 ➝ $120.00	Low
1/27/2020	Wedbush	Reiterated Rating	Buy	$237.00	High
12/15/2019	Wedbush	Reiterated Rating	Buy	$237.00	Medium
12/10/2019	Credit Suisse Group	Reiterated Rating	Buy	$113.00	Low
12/3/2019	Bank of America	Initiated Coverage	Underperform	$80.00	High
11/1/2019	HC Wainwright	Reiterated Rating	Hold	$85.00	Low
9/13/2019	Cowen	Set Target	Hold	$118.00	Low
8/1/2019	Wedbush	Reiterated Rating	Buy	$273.00	Low
8/1/2019	LADENBURG THALM/SH SH	Upgrade	Neutral ➝ Buy	$103.00 ➝ $106.00	High
8/1/2019	Jefferies Financial Group	Upgrade	Underperform ➝ Hold	$90.00	High
7/1/2019	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$98.00 ➝ $101.00	High
5/17/2019	UBS Group	Upgrade	Sell ➝ Neutral	$115.00 ➝ $94.00	Medium
5/9/2019	Credit Suisse Group	Upgrade	Underperform ➝ Neutral	$98.00	Medium
5/8/2019	Wedbush	Set Target	Buy	$273.00	Medium
5/2/2019	Wedbush	Boost Target	Outperform ➝ Outperform	$269.00 ➝ $273.00	High
5/1/2019	Cowen	Reiterated Rating	Hold	$103.00	High
4/9/2019	Oppenheimer	Lower Target	Outperform	$160.00 ➝ $155.00	Low
4/8/2019	Wedbush	Set Target	Buy	$269.00	High
3/26/2019	Oppenheimer	Set Target	Buy	$160.00	Low
3/26/2019	Credit Suisse Group	Reiterated Rating	Underperform	$105.00 ➝ $98.00	Medium
3/19/2019	Oppenheimer	Reiterated Rating	Buy		Medium
3/1/2019	Barclays	Lower Target	Underweight ➝ Underweight	$100.00 ➝ $95.00	Low
2/28/2019	LADENBURG THALM/SH SH	Set Target	Hold	$124.00	Low
2/27/2019	Cowen	Reiterated Rating	Hold	$109.00	Low
11/20/2018	Oppenheimer	Set Target	Buy	$160.00	Low
11/19/2018	Credit Suisse Group	Boost Target	Underperform ➝ Sell	$103.00 ➝ $105.00	Medium
11/15/2018	Cowen	Set Target	Hold	$106.00	High
11/2/2018	JPMorgan Chase & Co.	Boost Target	Neutral ➝ Neutral	$118.00 ➝ $126.00	Low
11/1/2018	Credit Suisse Group	Lower Target	Underperform ➝ Underperform	$106.00 ➝ $103.00	Low
11/1/2018	HC Wainwright	Reiterated Rating	Hold	$95.00	High
10/31/2018	Cowen	Set Target	Hold	$106.00	High
10/12/2018	Standpoint Research	Upgrade	Hold ➝ Buy		Low
9/27/2018	Wedbush	Set Target	Buy	$253.00	High
9/4/2018	Wedbush	Set Target	Buy	$253.00	High
8/13/2018	HC Wainwright	Set Target	Hold	$95.00	Medium
8/8/2018	Wedbush	Set Target	Buy	$253.00	Low
8/8/2018	Credit Suisse Group	Downgrade	Neutral ➝ Underperform		Low
8/2/2018	Cowen	Reiterated Rating	Hold	$110.00	Medium
8/2/2018	Barclays	Reiterated Rating	Sell	$100.00	High
8/2/2018	HC Wainwright	Reiterated Rating	Hold	$95.00	High
8/2/2018	Wedbush	Boost Target	Outperform ➝ Outperform	$234.00 ➝ $253.00	High
7/10/2018	Credit Suisse Group	Boost Target	Neutral ➝ Neutral	$104.00 ➝ $107.00	Medium

(Data available from 6/2/2018 forward)

News Sentiment Rating

1.12 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

10 very positive mentions
10 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/3/2022

8 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/3/2022

9 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/2/2023

12 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/1/2023

15 very positive mentions
8 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

3/3/2023

17 very positive mentions
11 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/2/2023

15 very positive mentions
21 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/2/2023

19 very positive mentions
17 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

6/1/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Today's Range

Now: $214.38

$212.99

$215.46

50 Day Range

MA: $220.48

$205.19

$232.99

52 Week Range

Now: $214.38

$201.65

$283.09

Volume

38,635 shs

Average Volume

494,468 shs

Market Capitalization

$10.04 billion

P/E Ratio

14.44

Dividend Yield

N/A

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of United Therapeutics?: The following sell-side analysts have issued research reports on United Therapeutics in the last twelve months: Argus, Bank of America Co., HC Wainwright, JPMorgan Chase & Co., LADENBURG THALM/SH SH, Morgan Stanley, Oppenheimer Holdings Inc., StockNews.com, The Goldman Sachs Group, Inc., UBS Group AG, and Wedbush.
View the latest analyst ratings for UTHR.
What is the current price target for United Therapeutics?: 9 Wall Street analysts have set twelve-month price targets for United Therapeutics in the last year. Their average twelve-month price target is $294.67, suggesting a possible upside of 38.0%. Oppenheimer Holdings Inc. has the highest price target set, predicting UTHR will reach $375.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $230.00 for United Therapeutics in the next year.
View the latest price targets for UTHR.
What is the current consensus analyst rating for United Therapeutics?: United Therapeutics currently has 2 sell ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UTHR will outperform the market and that investors should add to their positions of United Therapeutics.
View the latest ratings for UTHR.
What other companies compete with United Therapeutics?: Other companies that are similar to United Therapeutics include Ionis Pharmaceuticals, Madrigal Pharmaceuticals, Alkermes, Amicus Therapeutics and ImmunoGen. Learn More about companies similar to United Therapeutics.
How do I contact United Therapeutics' investor relations team?: United Therapeutics' physical mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company's listed phone number is (301) 608-9292 and its investor relations email address is [email protected]. The official website for United Therapeutics is www.unither.com. Learn More about contacing United Therapeutics investor relations.

United Therapeutics - UTHR Stock Price Target and Predictions

Analyst Price Target for UTHR

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

1.12 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of United Therapeutics?

What is the current price target for United Therapeutics?

What is the current consensus analyst rating for United Therapeutics?

What other companies compete with United Therapeutics?

How do I contact United Therapeutics' investor relations team?